Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25174282 | 0.89 | BACE1 (0.33) | BACE1BACE2USP30PRMT5WDR77 | |
| SCHEMBL30369811 | 0.89 | BACE1 (0.33) | BACE1BACE2USP30PRMT5WDR77 | |
| SCHEMBL21058443 | 0.85 | AAK1 (0.35) | BACE1BACE2USP30AAK1LIPE | |
| SCHEMBL25029120 | 0.85 | USP30 (0.31) | USP30AAK1 | |
| SCHEMBL29361413 | 0.85 | USP30 (0.31) | USP30AAK1 | |
| SCHEMBL17504507 | 0.84 | JAK2 (0.31) | — | |
| SCHEMBL23330822 | 0.83 | JAK2 (0.41) | BACE1BACE2USP30AAK1PRMT5 | |
| SCHEMBL20689530 | 0.81 | USP30 (0.33) | USP30PRMT5WDR77 | |
| SCHEMBL22724821 | 0.81 | HTR6 (0.40) | USP30AAK1LIPEPRMT5WDR77 | |
| SCHEMBL25028819 | 0.80 | HTR6 (0.34) | BACE1BACE2USP30AAK1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573920-B | Indoles for use in influenza virus infection | 爱尔兰詹森科学公司 | 2020-11-10 | — | — | CN | disclosed |
| US-10597390-B2 | Indoles for use in influenza virus infection | JANSSEN SCIENCES IRELAND UC (IE) | 2020-03-24 | — | — | US | disclosed |
| US-10597390-B2 | Indoles for use in influenza virus infection | JANSSEN SCIENCES IRELAND UC (IE) | 2020-03-24 | — | — | US | disclosed |
| US-20190185456-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-08-10 | — | — | US | disclosed |
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-08-10 | — | — | US | disclosed |
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-08-10 | — | — | US | disclosed |
| WO-2016020526-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN SCIENCES IRELAND UC (IE) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185456-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | POLRMT, EIF2AK2, POLM | BACE1 2968/4885BACE2 2414/4885USP30 1402/4885 |
| US-10597390-B2 | Indoles for use in influenza virus infection | IDO1, IDO2, INMT | BACE1 2195/4885BACE2 2510/4885USP30 3311/4885 |
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | IDO1, IDO2, INMT | BACE1 2195/4885BACE2 2510/4885USP30 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.